期刊文献+

人类免疫缺陷病毒-1包膜糖蛋白gp41的表达及优化 被引量:1

Optimization of expression of human immunodeficiency virus type 1 envelope gp41 in E coli
原文传递
导出
摘要 目的优化HIV.1本地流行株06044sp4t蛋白表达设计,为gp41免疫原的制备提供实验基础。方法以含HIV.106044gp41基因的质粒为模板,采用聚合酶链反应(PCR)扩增gp41目的基因,分别构建原核表达载体pET26b:gp41T(含546—683f1.a片段)及去掉N一端(NHR)和C一端(CHR)七价重复序列中间部分loop区(582~627aa)的pET26b—Sr41T(AL),经测序确认后,转化至大肠杆菌感受态细胞BL21(DE3)中,IPTG诱导表达。用聚丙烯酰氨凝胶电泳(SDS-PAGE)及Westernblot检测并鉴定重组表达蛋白。优化了重组蛋白的诱导表达条件。结果pET26b-gp41T和pET26b—gp41T(AL)重组表达质粒均能表达gp41蛋白,glMlT(△L)蛋白表达量高于gp41T;不同IPTG浓度诱导的蛋白表达量没有区别;用1mmol/LIPTG诱导后,37℃条件下表达量最高。Westernblot结果显示,gp41T(△L)与His抗体结合性能好。结论实验获得了稳定表达HIV-106044gp41的原核表达载体以及表达条件,为大量制备gp41蛋白免疫原奠定了基础。 Objective To optimize the expression of HIV-1 envelope gp41 in E coli. Methods The HIV-1 06044 gp41 gene encoding 546 - 683 aa was amplified by PCR and the prokaryotic expression plasmid pET26b-gp41T was constructed. Meanwhile ,plasmid pET26b-gp41T (△L) lacking the loop (582- 627aa) be- tween NHR and CHR of gp41 was also constructed. After identification by sequencing,the plasmids were trans- formed into E. coli BL21 ( DE3 ) and the protein expression was induced by Isopropyl β-D-l-thiogalactopyrano- side (IPTG) and analyzed by polypropylene aeyl ammonia gel electrophoresis (SDS-PAGE) and Western Blot. The protein expression condition was optimized. Results The pET26b-gp41T and pET26b-gp41T (AL) can express specific gp41 protein. Under lmmol/L IPTG induction,the gp41T(AL) protein expression quantity was higher than gp41T and the best expression was at 37 ℃. Comparing with gp41T,gp41T (AL) protein showed better affinity to his antibody. Conclusion We successfully constructed a recombinant plasmid that can express gp41 protein successfully in E eoli with well exposure of His-Tag. This will facilitate the production and purifica- tion of gp41 immunogen.
出处 《国际免疫学杂志》 CAS 2016年第2期101-106,共6页 International Journal of Immunology
关键词 人类免疫缺陷病毒-1 GP41 原核表达 优化 HIV-1 Gp41 Prokaryotic expression Modification
  • 相关文献

参考文献3

二级参考文献17

  • 1赵文锋,徐旭东,吴梧桐.幽门螺杆菌尿素酶B亚单位表位融合肽在大肠杆菌中的表达与纯化[J].药物生物技术,2007,14(4):235-240. 被引量:2
  • 2Constantine N T. Serological tests for the retroviruses: approaching a decade of evolution[ J ]. AIDS, 1993,7 ( 1 ) : 1-13.
  • 3Sven-Holger D, Tomas P, Peter H, et al. Fine mapping of an immunodominant region of the transmembrane protein of the human immunodefieieney virus (HIV-1)[ J]. J Virol Method,1989,25 (2):167- 177.
  • 4Harrison SC. Viral membrane fusion[J]. Nat Struct Mol Biol, 2008, 15(7): 690-8.
  • 5Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus[J]. Nat Rev Microbiol, 2008, 6(2): 143-55.
  • 6Hoxie JA. Toward an antibody-based HIV-1 vaccine[J]. Annu Rev Med, 2010, 61: 135-52.
  • 7Bosch ML, Earl PL, Fargnoli K, et al. Identification of the fusion peptide of primate immunodeficiency viruses[J]. Science, 1989, 244 (4905): 694-7.
  • 8Gallaher WR. Detection of a fusion peptide sequence in the transmembrane protein of human immunodefieiency virus[J]. Cell, 1987, 50(3): 327-8.
  • 9Liu S, Wu S, Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds [J]. Curr Pharm Des, 2007. 13(2): 143-62.
  • 10Nelson JD, Kinkead H, Brunel FM, et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics[J]. Virology, 2008, 377(1): 170-83.

共引文献26

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部